Cipla, country’s largest drug maker has reportedly slashed the prices of three anti-cancer drugs - Erlotinib (ERLOCIP), Docetaxel (DOCETAX) and Capecitabine (CAPEGARD). These drugs are used for the treatment of lung and pancreatic cancer, breast cancer, head and neck cancer, gastric cancer, bladder, colorectal and colon cancers.
The company has reported 61.83% rise in its net profit at Rs 500.01 crore as compared to Rs 308.97 crore for the same quarter in the previous year. Total income from operation of the company has increased by 23.86% at Rs 2191.84 crore for quarter under review as compared to Rs 1769.66 crore for the quarter ended September 30, 2011.
